Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies.

Sebastian Ochoa, Li Ding, Samantha Kreuzburg, Jennifer Treat, Steven M Holland, Christa S Zerbe

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Jun 15

filter terms:

Patients with autoantibodies to interferon-γ (IFN-γ) may develop severe nontuberculous mycobacterial infections. We describe the novel use of daratumumab in a patient with autoantibodies to IFN-γ who had progressive infection, resulting in clinical and radiographic improvement. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Citation

Sebastian Ochoa, Li Ding, Samantha Kreuzburg, Jennifer Treat, Steven M Holland, Christa S Zerbe. Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Jun 15;72(12):2206-2208